Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company's senior executives presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ongoing in Berlin, Germany.

19 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the University of California, San Francisco (UCSF), have received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

16 Nov 2010

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

PolyMedix, Inc, an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that data from two Phase 1B/2 clinical studies with PMX-60056 were presented today, in oral and poster sessions, at the Annual American Heart Association Scientific Sessions Meeting. PMX-60056 is a synthetic, small-molecule designed to reverse the anti-clotting effects of both heparin and low molecule weight heparin (LMWH).

16 Nov 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Scientists from Biodel Inc. reported new findings from the company's Linjeta, insulin glargine, "smart" basal insulin and stabilized glucagon development programs in poster presentations yesterday and today at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD.

15 Nov 2010

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.

12 Nov 2010

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

Milestone Scientific Inc., the recognized leader in advanced, computer controlled drug delivery technologies, and Ordway Research Institute, a leading research and drug development organization, have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs and cancerous tissue through Milestone's patented CompuFlo injection technology.

12 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Adolor receives U.S. Patent for beloxepin to treat pain

Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.

11 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMX-30063, a synthetic defensin-mimetic antibiotic.

11 Nov 2010

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.

9 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta.

8 Nov 2010

Pharmacokinetics News and Research

Further Reading

VYTORIN reduces major vascular events in patients with chronic kidney disease

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Merck wins third FOSAMAX bellwether trial

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

PolyMedix presents data on PMX-60056 Phase 1B/2 studies for blood clotting at American Heart Association

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Adolor receives U.S. Patent for beloxepin to treat pain

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

PolyMedix receives FDA regulatory clearance for PMX-30063 IND application

Omthera initiates ECLIPSE study for treatment of high triglycerides

XenoPort third quarter net loss decreases to $19.9 million

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News